MedTrace Logo

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

NCT02585895 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2022-11-30

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of subcutaneous (SC) evolocumab, compared to regularly scheduled low-density lipoprotein cholesterol (LDL-C) apheresis, on reducing the need for future apheresis.

Conditions

Interventions

BIOLOGICAL

Evolocumab

Administered by subcutaneous injection once every 2 weeks

PROCEDURE

Low-density Lipoprotein Cholesterol (LDL-C) Apheresis

Participants received apheresis for LDL-C according the their physician's prescription and local custom.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-21
Primary Completion
2016-09-01
Completion
2017-01-20
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Czechia
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02585895 on ClinicalTrials.gov